A Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
Latest Information Update: 16 Feb 2026
At a glance
- Drugs Integrin alpha4beta7 antagonists (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Ensho Therapeutics
Most Recent Events
- 16 Feb 2026 New trial record